Stockreport

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting [Yahoo! Finan...

Vir Biotechnology, Inc.  (VIR) 
PDF – No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate – – Late-breaking oral presentation of MARCH Part B st [Read more]